Biotech Values

[dewophile]

mnta

"a best-case scenario FDA decision with m-enox in 2009 might give us a the Vanda-like spike.
Who knows what the market psychology will be in 2010. Maybe in 2010 we see smaller fireworks"

psychology aside, the bottom line fundamentally is that IF MNTA's lovenox anda is the solely approved generic it deserves a huge spike - not just for the obvious commercial implications of the approval, but as many have said for the validation of the technology, particularly as it pertains to FOBs since differences in glycosylation patterns are what is central to the whole FOB debate since the protein backbone is readily duplicated in cell culture